A nanotherapeutic approach for fighting the odds against the malignant disorders
Source abstract
Abstract
Cancer, a combination of haematological and neoplastic malignancies, is a dreadful disease accounting for major fatalities worldwide. The domain of innovative nanoparticle-based technology has revolutionized the field of cancer therapeutics and imaging. With an emphasis on various nano-immunotherapeutic approaches, this study highlights the most recent developments in nano-immune engineering for metastatic tumours. Nanotechnology-based cancer immunotherapy has powered the (i) activation of T-cells in the tumour microenvironment (TME), (ii) preparation of efficient nanovaccines via nano-carriers and (iii) generation of smart nanomaterials which change their size/shape (size range of 1 to 1000 nm) and functionality upon activation in TME. The tumour microenvironment has an important, albeit contentious, role in controlling nanoparticle (NP) dispersion and subsequent biological consequences. The current study promotes the harnessing of potential peripheral immune cells by avoiding the creation of a pre-metastatic niche and, thus, suppressing tumour recurrence. This review descriptively accounts for a wide array of nanomaterials based on their polymeric constituents. Moreover, the current article explores the obstacles of integrating nanoscale immunomodulators and presents a forward-looking view of the novel nanotechnology-based approaches that may eventually prove helpful in eliminating metastatic illnesses.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. “Cancer.” https://www.who.int/news-room/fact-sheets/detail/cancer (accessed Jun. 28, 2022)
2. Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ (2021) Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol 16(1):25–36. https://doi.org/10.1038/S41565-020-00822-Y10.1038/S41565-020-00822-Y ↗
3. O’Leary MC et al (2019) FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 25(4):1142–1146. https://doi.org/10.1158/1078-0432.CCR-18-203510.1158/1078-0432.CCR-18-2035 ↗
4. Bouchkouj N et al (2019) FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 25(6):1702–1708. https://doi.org/10.1158/1078-0432.CCR-18-274310.1158/1078-0432.CCR-18-2743 ↗
5. Guedan S, Ruella M, June CH (2019) Emerging cellular therapies for cancer. Annu Rev Immunol 37:145–171. https://doi.org/10.1146/annurev-immunol-042718-04140710.1146/annurev-immunol-042718-041407 ↗
6. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365. https://doi.org/10.1126/science.aar671110.1126/science.aar6711 ↗
7. Saini S, Kumar Y (2021) “Bispecific antibodies: a promising entrant in cancer immunotherapy,” Translational biotechnology: a journey from laboratory to clinics, pp 233–266. https://doi.org/10.1016/B978-0-12-821972-0.00014-910.1016/B978-0-12-821972-0.00014-9 ↗
8. Zhang P et al (2021) Nanotechnology-enhanced immunotherapy for metastatic cancer. The Innovation 2(4):100174. https://doi.org/10.1016/J.XINN.2021.10017410.1016/J.XINN.2021.100174 ↗
9. Schuster M, Nechansky A, Loibner H, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1(2):138–147. https://doi.org/10.1002/BIOT.20050004410.1002/BIOT.200500044 ↗
10. Kalos M et al (2011) T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. https://doi.org/10.1126/SCITRANSLMED.300284210.1126/SCITRANSLMED.3002842 ↗
11. Tang J, Shen D, Zhang J, Ligler FS, Cheng K (2015) Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done. Expert Opin Biol Ther 15(9):1251. https://doi.org/10.1517/14712598.2015.104994410.1517/14712598.2015.1049944 ↗
12. Singh R, Sharma A, Saji J, Umapathi A, Kumar S, Daima HK (2022) Smart nanomaterials for cancer diagnosis and treatment. Nano Converg 9(1):1–39. https://doi.org/10.1186/S40580-022-00313-X10.1186/S40580-022-00313-X ↗
13. Wang Y, Zhang L, Guo S, Hatefi A, Huang L (2013) Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release 172(1):179–189. https://doi.org/10.1016/J.JCONREL.2013.08.01510.1016/J.JCONREL.2013.08.015 ↗
14. Chang HI, Yeh MK (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 7:49. https://doi.org/10.2147/IJN.S2676610.2147/IJN.S26766 ↗
15. Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK (2019) Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 6(1):1–30. https://doi.org/10.1186/S40580-019-0193-210.1186/S40580-019-0193-2 ↗
16. Nel AE et al (2009) Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater 8(7):543–557. https://doi.org/10.1038/nmat244210.1038/nmat2442 ↗
17. Smith DM, Simon JK, Baker JR (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13(8):592–605. https://doi.org/10.1038/nri348810.1038/nri3488 ↗
18. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T (2015) Synthetic nanoparticles for vaccines and immunotherapY. Chem Rev 115(19):11109–11146. https://doi.org/10.1021/ACS.CHEMREV.5B00109/ASSET/IMAGES/ACS.CHEMREV.5B00109.SOCIAL.JPEG_V0310.1021/ACS.CHEMREV.5B00109/ASSET/IMAGES/ACS.CHEMREV.5B00109.SOCIAL.JPEG_V03 ↗
19. Bignold LP (2020) “Immunotherapies”. Principles of Tumors, pp 419–438. https://doi.org/10.1016/B978-0-12-816920-9.00016-X10.1016/B978-0-12-816920-9.00016-X ↗
20. Shams F et al (2022) Nanotechnology-based products for cancer immunotherapy. Mol Biol Rep 49(2):1389–1412. https://doi.org/10.1007/S11033-021-06876-Y10.1007/S11033-021-06876-Y ↗
21. Nano-enabled immunomodulation (2021). Nat Nanotechnol 16:1. https://doi.org/10.1038/s41565-020-00842-810.1038/s41565-020-00842-8 ↗
22. Yang M, Li J, Gu P, Fan X (2021) The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater 6(7):1973–1987. https://doi.org/10.1016/J.BIOACTMAT.2020.12.01010.1016/J.BIOACTMAT.2020.12.010 ↗
23. Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(23):5591–5596. https://doi.org/10.1242/JCS.11639210.1242/JCS.116392 ↗
24. Sushnitha M, Evangelopoulos M, Tasciotti E, Taraballi F (2020) Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. Front Bioeng Biotechnol 8:627. https://doi.org/10.3389/FBIOE.2020.00627/BIBTEX10.3389/FBIOE.2020.00627/BIBTEX ↗
25. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.333010.1038/nbt.3330 ↗
26. Wang L, Huo M, Chen Y, Shi J (2018) Tumor microenvironment-enabled nanotherapy. Adv Healthc Mater 7(8):1701156. https://doi.org/10.1002/ADHM.20170115610.1002/ADHM.201701156 ↗
27. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423–1437. https://doi.org/10.1038/nm.339410.1038/nm.3394 ↗
28. Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1:10–19. https://doi.org/10.1016/J.SMAIM.2020.04.00110.1016/J.SMAIM.2020.04.001 ↗
29. Miao L, Huang L (2015) Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res 166:193. https://doi.org/10.1007/978-3-319-16555-4_910.1007/978-3-319-16555-4_9 ↗
30. Ahmad F, Wang X, Li W (2019) Toxico-metabolomics of engineered nanomaterials: progress and challenges. Adv Funct Mater 29(51):1904268. https://doi.org/10.1002/ADFM.20190426810.1002/ADFM.201904268 ↗
31. Westmeier D et al (2018) Nanoparticle binding attenuates the pathobiology of gastric cancer-associated Helicobacter pylori. Nanoscale 10(3):1453–1463. https://doi.org/10.1039/C7NR06573F10.1039/C7NR06573F ↗
32. Cao L, Yuan J, Chen M, Shangguan W (2010) Photocatalytic energy storage ability of TiO2-WO3 composite prepared by wet-chemical technique. J Environ Sci 22(3):454–459. https://doi.org/10.1016/S1001-0742(09)60129-710.1016/S1001-0742(09)60129-7 ↗
33. Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21(2):193–215. https://doi.org/10.1016/J.DEVCEL.2011.07.00110.1016/J.DEVCEL.2011.07.001 ↗
34. Inoue S (1989) Ultrastructure of basement membranes. Int Rev Cytol 117(C):57–98. https://doi.org/10.1016/S0074-7696(08)61334-010.1016/S0074-7696(08)61334-0 ↗
35. Yokoi K, Kojic M, Milosevic M, Tanei T, Ferrari M, Ziemys A (2014) Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res 74(16):4239–4246. https://doi.org/10.1158/0008-5472.CAN-13-3494/657846/AM/CAPILLARY-WALL-COLLAGEN-AS-A-BIOPHYSICAL-MARKER-OF10.1158/0008-5472.CAN-13-3494/657846/AM/CAPILLARY-WALL-COLLAGEN-AS-A-BIOPHYSICAL-MARKER-OF ↗
36. Singh M, Ma R, Zhu L (2021) Theoretical evaluation of enhanced gold nanoparticle delivery to PC3 tumors due to increased hydraulic conductivity or recovered lymphatic function after mild whole body hyperthermia. Med Biol Eng Comput 59(2):301–313. https://doi.org/10.1007/S11517-020-02308-410.1007/S11517-020-02308-4 ↗
37. Nikmaneshi MR, Firoozabadi B, Mozafari A, Munn LL (2020) A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth. Sci Rep 10(1):1–20. https://doi.org/10.1038/s41598-020-59658-010.1038/s41598-020-59658-0 ↗
38. El-Kareh AW, Secomb TW 1995 “Effect of increasing vascular hydraulic conductivity on delivery of macromolecular drugs to tumor cells”. Int J Radiat Oncol*Biol*Phys 32(5):1419–1423. https://doi.org/10.1016/0360-3016(95)00110-K10.1016/0360-3016(95)00110-K ↗
39. Kanapathipillai M, Brock A, Ingber DE (2014) Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev 79–80:107–118. https://doi.org/10.1016/J.ADDR.2014.05.00510.1016/J.ADDR.2014.05.005 ↗
40. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801–1815. https://doi.org/10.1016/S0002-9440(10)63540-710.1016/S0002-9440(10)63540-7 ↗
41. Yurchenco PD, Ruben GC (1987) Basement membrane structure in situ: evidence for lateral associations in the type IV collagen network. J Cell Biol 105(6):2559–2568. https://doi.org/10.1083/JCB.105.6.255910.1083/JCB.105.6.2559 ↗
42. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47(12):3039–3051
43. Puri A et al (2009) “Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic”, Critical Reviews&trade. Therapeutic Drug Carrier Systems 26(6):523–580. https://doi.org/10.1615/CRITREVTHERDRUGCARRIERSYST.V26.I6.1010.1615/CRITREVTHERDRUGCARRIERSYST.V26.I6.10 ↗
44. Samir A, Elgamal BM, Gabr H, Sabaawy HE (2015) Nanotechnology applications in hematological malignancies (Review). Oncol Rep 34(3):1097. https://doi.org/10.3892/OR.2015.410010.3892/OR.2015.4100 ↗
45. Ferrara F, Schiffer CA (2013) Acute myeloid leukaemia in adults. The Lancet 381(9865):484–495. https://doi.org/10.1016/S0140-6736(12)61727-910.1016/S0140-6736(12)61727-9 ↗
46. Zhuang J, Holay M, Park JH, Fang RH, Zhang J, Zhang L (2019) Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics 9(25):7826–7848. https://doi.org/10.7150/THNO.3721610.7150/THNO.37216 ↗
47. Dubensky TW, Reed SG (2010) Adjuvants for cancer vaccines. Semin Immunol 22(3):155–161. https://doi.org/10.1016/J.SMIM.2010.04.00710.1016/J.SMIM.2010.04.007 ↗
48. Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS (2016) Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016:1459394. https://doi.org/10.1155/2016/145939410.1155/2016/1459394 ↗
49. Smith TT et al (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nano-carriers. Nat Nanotechnol 12(8):813–820. https://doi.org/10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
50. García KP et al (2014) Zwitterionic-coated ‘stealth’ nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small 10(13):2516–2529. https://doi.org/10.1002/SMLL.20130354010.1002/SMLL.201303540 ↗
51. McMahon HT, Boucrot E (2011) Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12(8):517–533. https://doi.org/10.1038/nrm315110.1038/nrm3151 ↗
52. Cevaal PM et al (2021) In vivo T cell-targeting nanoparticle drug delivery systems: considerations for rational design. ACS Nano 15(3):3736–3753. https://doi.org/10.1021/ACSNANO.0C09514/ASSET/IMAGES/MEDIUM/NN0C09514_0008.GIF10.1021/ACSNANO.0C09514/ASSET/IMAGES/MEDIUM/NN0C09514_0008.GIF ↗
53. Selby LI, Cortez-Jugo CM, Such GK, Johnston APR (2017) Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(5):e1452. https://doi.org/10.1002/WNAN.145210.1002/WNAN.1452 ↗
54. Dai Q, Bertleff-Zieschang N, Braunger JA, Björnmalm M, Cortez-Jugo C, Caruso F (2018) Particle targeting in complex biological media. Adv Healthc Mater 7(1):1700575. https://doi.org/10.1002/ADHM.20170057510.1002/ADHM.201700575 ↗
55. Schmid D et al (2017) “T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun 8(1):1–12. https://doi.org/10.1038/s41467-017-01830-810.1038/s41467-017-01830-8 ↗
56. Hao M, Chen B, Zhao X, Zhao N, Xu FJ (2020) Organic/inorganic nanocomposites for cancer immunotherapy. Mater Chem Front 4(9):2571–2609. https://doi.org/10.1039/D0QM00323A10.1039/D0QM00323A ↗
57. Lee J, Chatterjee DK, Lee MH, Krishnan S (2014) Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett 347(1):46–53. https://doi.org/10.1016/J.CANLET.2014.02.00610.1016/J.CANLET.2014.02.006 ↗
58. Paul W, Sharma CP (2020) Inorganic nanoparticles for targeted drug delivery. Biointegration of Medical Implant Materials. https://doi.org/10.1016/B978-0-08-102680-9.00013-510.1016/B978-0-08-102680-9.00013-5 ↗
59. Santos HA, Bimbo LM, Peltonen L, Hirvonen J (2015) Chapter 18: Inorganic Nanoparticles in Targeted Drug Delivery and Imaging (Book Chapter). In: Sanyog J, Devarajan P (eds) Targeted drug delivery – concepts and design (Advances in Delivery Science and Technology). Springer International Publishing, pp 571–61310.1007/978-3-319-11355-5_18 ↗
60. Bayda S et al (2017) Inorganic nanoparticles for cancer therapy: a transition from lab to clinic. Curr Med Chem 25(34):4269–4303. https://doi.org/10.2174/092986732566617122914115610.2174/0929867325666171229141156 ↗
61. Lôbo GCNB, Paiva KLR, Silva ALG, Simões MM, Báo SN, Radicchi MA (2021) Nano-carriers used in drug delivery to enhance immune system in cancer therapy. Pharmaceutics 13(8):1167. https://doi.org/10.3390/PHARMACEUTICS1308116710.3390/PHARMACEUTICS13081167 ↗
62. Lim J, Yeap SP, Che HX, Low SC (2013) Characterization of magnetic nanoparticle by dynamic light scattering. Nanoscale Res Lett 8(1):1–14. https://doi.org/10.1186/1556-276X-8-381/FIGURES/1010.1186/1556-276X-8-381/FIGURES/10 ↗
63. Wang F et al (2018) Dextran coated Fe3O4 nanoparticles as a near-infrared laser-driven photothermal agent for efficient ablation of cancer cells in vitro and in vivo. Mater Sci Eng C 90:46–56. https://doi.org/10.1016/J.MSEC.2018.04.03010.1016/J.MSEC.2018.04.030 ↗
64. Singh A, Sahoo SK (2014) Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discov Today 19(4):474–481. https://doi.org/10.1016/J.DRUDIS.2013.10.00510.1016/J.DRUDIS.2013.10.005 ↗
65. Luk BT, Zhang L (2014) Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces 6(24):21859–21873. https://doi.org/10.1021/AM5036225/ASSET/IMAGES/LARGE/AM-2014-036225_0010.JPEG10.1021/AM5036225/ASSET/IMAGES/LARGE/AM-2014-036225_0010.JPEG ↗
66. Sun C, Lee JSH, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60(11):1252–1265. https://doi.org/10.1016/J.ADDR.2008.03.01810.1016/J.ADDR.2008.03.018 ↗
67. Zanganeh S et al (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11(11):986–994. https://doi.org/10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
68. Mukherjee S, Liang L, Veiseh O (2020) Recent advancements of magnetic nanomaterials in cancer therapy. Pharmaceutics 12(2):147. https://doi.org/10.3390/pharmaceutics1202014710.3390/pharmaceutics12020147 ↗
69. Dulińska-Litewka J, Łazarczyk A, Hałubiec P, Szafrański O, Karnas K, Karewicz A (2019) Superparamagnetic iron oxide nanoparticles-current and prospective medical applications. Materials (Basel) 12(4):617. https://doi.org/10.3390/ma1204061710.3390/ma12040617 ↗
70. Montaseri H, Kruger CA, Abrahamse H (2021) Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer. Pharmaceutics 13(3):296. https://doi.org/10.3390/PHARMACEUTICS1303029610.3390/PHARMACEUTICS13030296 ↗
71. Salunkhe AB, Khot VM, Pawar SH (2014) Magnetic hyperthermia with magnetic nanoparticles: a status review. Curr Top Med Chem 14(5):572–594. https://doi.org/10.2174/156802661466614011820355010.2174/1568026614666140118203550 ↗
72. Ramishetti S et al (2015) Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9(7):6706–6716. https://doi.org/10.1021/ACSNANO.5B0279610.1021/ACSNANO.5B02796 ↗
73. Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ (2013) In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release 172(2):426–435. https://doi.org/10.1016/J.JCONREL.2013.05.03710.1016/J.JCONREL.2013.05.037 ↗
74. Kim SS et al (2010) RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 18(2):370–376. https://doi.org/10.1038/MT.2009.27110.1038/MT.2009.271 ↗
75. Ou W et al (2018) Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release 281:84–96. https://doi.org/10.1016/J.JCONREL.2018.05.01810.1016/J.JCONREL.2018.05.018 ↗
76. Dunn ZS, Mac J, Wang P (2019) “T cell immunotherapy enhanced by designer biomaterials”. Biomaterials 217. https://doi.org/10.1016/J.BIOMATERIALS.2019.11926510.1016/J.BIOMATERIALS.2019.119265 ↗
77. Lee CK, Atibalentja DF, Yao LE, Park J, Kuruvilla S, Felsher DW (2022) Anti-PD-L1 F(ab) conjugated PEG-PLGA nanoparticle enhances immune checkpoint therapy. Nanotheranostics 6(3):243. https://doi.org/10.7150/NTNO.6554410.7150/NTNO.65544 ↗
78. Ding Q et al (2015) Targeting and liposomal drug delivery to CD40L expressing T cells for treatment of autoimmune diseases. J Control Release 207:86–92. https://doi.org/10.1016/J.JCONREL.2015.03.03510.1016/J.JCONREL.2015.03.035 ↗
79. Yang YSS et al (2018) Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles. Biomater Sci 7(1):113–124. https://doi.org/10.1039/C8BM01208C10.1039/C8BM01208C ↗
80. Xie Y et al (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120–129. https://doi.org/10.1016/J.JCONREL.2016.03.02910.1016/J.JCONREL.2016.03.029 ↗
81. Kandil R, Xie Y, Heermann R, Isert L, Jung K, Mehta A, Merkel OM (2019) Coming in and finding out: blending receptor-targeted delivery and efficient endosomal escape in a novel bio-responsive sirna delivery system for gene knockdown in Pulmonary T cells. Adv Ther (Weinh) 2(7):1900047. https://doi.org/10.1002/adtp.20190004710.1002/adtp.201900047 ↗
82. Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP (2017) Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth. ACS Nano 11(6):5417–5429. https://doi.org/10.1021/ACSNANO.6B08152/SUPPL_FILE/NN6B08152_SI_001.PDF10.1021/ACSNANO.6B08152/SUPPL_FILE/NN6B08152_SI_001.PDF ↗
83. Soenen S, Rivera-Gil P, Montenegro J-M, Parak WJ, De Smedt S, Braeckmans K (2011) Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. NANO TODAY 6(5):446–465. https://doi.org/10.1016/j.nantod.2011.08.00110.1016/J.NANTOD.2011.08.001 ↗
84. Devi S et al (2022) Quantum dots: an emerging approach for cancer therapy. Front Mater 8:585. https://doi.org/10.3389/FMATS.2021.798440/BIBTEX10.3389/FMATS.2021.798440/BIBTEX ↗
85. Chen L, Liang J (2020) An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng: C 112:110924. https://doi.org/10.1016/J.MSEC.2020.11092410.1016/J.MSEC.2020.110924 ↗
86. Wen L et al (2014) Labeling the nucleocapsid of enveloped baculovirus with quantum dots for single-virus tracking. Biomaterials 35(7):2295–2301. https://doi.org/10.1016/J.BIOMATERIALS.2013.11.06910.1016/J.BIOMATERIALS.2013.11.069 ↗
87. S. Tope, S. Saudagar, N. Kale, S. Khambayat, and K. Bhise, “Review: therapeutic application of quantum dots (QD),” THE PHARMA INNOVATION-JOURNAL, vol. 2, no. 12, 2014, Accessed: Jun. 28, 2022. [Online]. Available: www.thepharmajournal.com
88. Tang L et al (2022) Multifunctional inorganic nanomaterials for cancer photoimmunotherapy. Cancer Commun 42(2):141–163. https://doi.org/10.1002/CAC2.1225510.1002/CAC2.12255 ↗
89. Song G et al (2019) Toxicity of functionalized multi-walled carbon nanotubes on bone mesenchymal stem cell in rats. Dent Mater J 38(1):127–135. https://doi.org/10.4012/DMJ.2017-31310.4012/DMJ.2017-313 ↗
90. Hesp NCH et al (2021) “Nano-imaging photoresponse in a moiré unit cell of minimally twisted bilayer graphene”. Nat Commun 12(1). https://doi.org/10.1038/S41467-021-21862-510.1038/S41467-021-21862-5 ↗
91. Sharma H, Mondal S (2020) Functionalized graphene oxide for chemotherapeutic drug delivery and cancer treatment: a promising material in nanomedicine. Int J Mol Sci 21(17):6280. https://doi.org/10.3390/IJMS2117628010.3390/IJMS21176280 ↗
92. Zheng Y et al (2021) “2D nanomaterials for tissue engineering and regenerative nanomedicines: recent advances and future challenges”. Adv Healthc Mater 10(7). https://doi.org/10.1002/ADHM.202001743.10.1002/ADHM.202001743 ↗
93. Karimi Shervedani R, Samiei Foroushani M, Kefayat A, Torabi M, Rahnemaye Rahsepar F (2018) Construction and characterization of a theranostic system based on graphene/manganese chelate. Biosens Bioelectron. 117:794–801. https://doi.org/10.1016/J.BIOS.2018.07.01110.1016/J.BIOS.2018.07.011 ↗
94. Choi Y et al (2020) Graphene oxide nanoribbon hydrogel: viscoelastic behavior and use as a molecular separation membrane. ACS Nano 14(9):12195–12202. https://doi.org/10.1021/ACSNANO.0C0590210.1021/ACSNANO.0C05902 ↗
95. Eskandari P, Abousalman-Rezvani Z, Roghani-Mamaqani H, Salami-Kalajahi M (2021) “Polymer-functionalization of carbon nanotube by in situ conventional and controlled radical polymerizations,. Adv Colloid Interface Sci 294:102471. https://doi.org/10.1016/J.CIS.2021.10247110.1016/J.CIS.2021.102471 ↗
96. Yang Z, Ma Y, Zhao H, Yuan Y, Kim BYS (2020) Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(2):e1590. https://doi.org/10.1002/WNAN.159010.1002/WNAN.1590 ↗
97. Hess KL, Medintz IL, Jewell CM (2019) Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today 27:73–98. https://doi.org/10.1016/J.NANTOD.2019.04.00510.1016/J.NANTOD.2019.04.005 ↗
98. Sharma A, Goyal AK, Rath G (2018) Recent advances in metal nanoparticles in cancer therapy. J Drug Target 26(8):617–632. https://doi.org/10.1080/1061186X.2017.140055310.1080/1061186X.2017.1400553 ↗
99. Shariatzadeh S et al (2022) Metallic nanoparticles for the modulation of tumor microenvironment; a new horizon. Front Bioeng Biotechnol 10:219. https://doi.org/10.3389/FBIOE.2022.847433/BIBTEX10.3389/FBIOE.2022.847433/BIBTEX ↗
100. Evans ER, Bugga P, Asthana V, Drezek R (2018) Metallic nanoparticles for cancer immunotherapy. Mater Today (Kidlington) 21(6):673. https://doi.org/10.1016/J.MATTOD.2017.11.02210.1016/J.MATTOD.2017.11.022 ↗